- No file added yet -

Budget impact and transferability of cost-effectiveness of DPYD testing in metastatic breast cancer in 3 health systems - supplementary material

dataset

posted on 2023-08-14, 09:39 authored by Rositsa Koleva-Kolarova, Heleen Vellekoop, Simone Huygens, Matthijs Versteegh, Maureen Rutten-van Mo¨ lken, La´ szlo´ Szilberhorn, Tama´ s Zelei, Bal ´ azs Nagy, Sarah Wordsworth, Apostolos Tsiachristas

Appendix Table 1. General (UK) model input parameters

Funding

Horizon 2020 Framework Programme, (Grant / Award Number '824997')

History

Usage metrics

Keywords

5-fluorouracil adverse drug reactions capecitabine cost–effectiveness cost-utility DPYD drug toxicity economic evaluation genetic testing metastatic breast cancer

Licence

CC BY-NC-ND 4.0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM